Ebola clinical management
Ebola virus disease (EVD) is a life-threatening disease caused by Ebola virus, with a pooled case fatality rate of 60% in outbreaks from 2010-2020. The clinical management and operations unit is supporting the delivery of patient centred, individualized critical care to reduce the case fatality of EVD through three key interventions.
Therapeutics for EVD
Optimized supportive care
Safe, patient-centred Ebola treatment centres
Therapeutics for EVD
The WHO Ebola Virus Disease (EVD) Clinical management: living guidance contains the Organization’s most up-to-date recommendations for the clinical management of people with EVD. Providing guidance that is comprehensive and holistic for the optimal care of patients with EVD throughout their illness is important.
The living guidance is available in both pdf format (via the ‘Download’ button) and via an online platform in both French and English, and is updated regularly as new evidence emerges.
This first version of the Clinical management for EVD living guidance contains four new recommendations regarding use of therapeutics for EVD, this includes two strong recommendations for the use of monoclonal antibody therapies. This new living guideline is written to accompany the optimized supportive care (oSoC) for EVD standard operating procedures (5, 6). The living guideline aims to summarize high quality evidence for EVD therapeutics and make recommendations for their use.
Posters
These posters are supportive tools based on the WHO Therapeutics for Ebola Virus Disease (EVD). They are intended to provide supportive information for healthcare workers who are prescribing, preparing, and administering the neutralizing monoclonal antibodies REGN-EB3 or mAb114 in patients with EVD.
Poster A and Poster B provide information on the following:
- Patient selection (Poster A)
- Dosage (Poster A)
- Preparation and dilution instructions for intravenous formulation (Poster B)
- Administration instructions (Poster B)
- Safety and monitoring considerations (Poster B)
The posters are available in both English and French in A2 and A4 size for download.
Hypersensitivity reactions including infusion-associated events have been reported during and post-infusion with mAb114. The most common adverse events...
Hypersensitivity reactions including infusion-associated events have been reported during and post-infusion with REGN-EB3. The most common adverse events...
Both the REGN-EB3 and mAb114 are recommended for use in EVD. The two drugs should not be given together. The choice of which monoclonal antibody to use...
Both mAb114 and REGN-EB3 are recommended for use in EVD. The two drugs should not be given together. The choice of which monoclonal antibody to use depends...
Highlights
12 March 2024
Filovirus disease clinical management working group
Meeting report, Geneva, Switzerland, 16–17 March 2023
Ebola virus disease resources
Key publications
11 August 2023
Infection prevention and control guideline for Ebola and Marburg disease, August 2023
Ebola and Marburg disease outbreaks remain important public health threats. The newly published WHO Infection prevention and control guideline...
1 January 2016
Recovery toolkit: supporting countries to achieve health service resilience: a library of tools and resources...
The overall goal of this Toolkit is to support countries in the reactivation of essential health services in the aftermath of a public health emergency....
In light of the decline in new Ebola cases, strategies are now needed to scale down the activities and bed capacities in Ebola care facilities. These facilities...
Posters with detailed instructions for health-care professionals on how to remove personal protective equipment (PPE) before and after visiting a treatment...
Posters with detailed instructions for health-care professionals on how put on and how to remove personal protective equipment (PPE) before and after visiting...